2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children

• Main Author: Kissling, Esther
• Publication Date: 2018
• Other Authors: Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, I-MOVE/I-MOVE+ study team
• Format: Article
• Language: eng
• Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Download full: http://hdl.handle.net/10400.18/5062
• topic: Case Control Study; Influenza; influenza Vaccine; Multicentre Study; Vaccine Effectiveness; Cuidados de Saúde; Efetividade da Vacina Antigripal; Vacina Antigripal; I-MOVE; I-MOVE+

Background:During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods:We used the test negative design in a multicentre case–control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients ainfluenza Vaccinend a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0–14, 15–64 and ≥65  years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0–14, 15–64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively. Conclusions: VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65  years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine.